COMMONLY REPORTED ADVERSE EVENTS ASSOCIATED WITH ANTICOAGULANTS USING FDA ADVERSE EVENT REPORTING SYSTEM DATABASE 2012-2018

被引：0
|
作者：
Costa, L. [1 ]
Hincapie, A. [1 ]
Guo, J. J. [1 ]
机构：
[1] Univ Cincinnati, Cincinnati, OH USA
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
10.1016/j.jval.2019.04.684
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDG5
引用
收藏
页码：S163 / S163
页数：1
相关论文
共 50 条
  • [21] Triptans and serious adverse vascular events: Data mining of the FDA Adverse Event Reporting System database
    Roberto, Giuseppe
    Piccinni, Carlo
    D'Alessandro, Roberto
    Poluzzi, Elisabetta
    CEPHALALGIA, 2014, 34 (01) : 5 - 13
  • [22] Novel Adverse Events of Bevacizumab in the US FDA Adverse Event Reporting System Database A Disproportionality Analysis
    Shamloo, Behrooz K.
    Chhabra, Pankdeep
    Freedman, Andrew N.
    Potosky, Arnold
    Malin, Jennifer
    Smith, Sheila Weiss
    DRUG SAFETY, 2012, 35 (06) : 507 - 518
  • [23] Pharmacovigilance analysis of orlistat adverse events based on the FDA adverse event reporting system (FAERS) database
    Zhu, Jinfeng
    Hu, Mianda
    Liang, Yingshi
    Zhong, Mingjun
    Chen, Zilin
    Wang, Zhenjie
    Yang, Yujia
    Luo, Ziyi
    Zeng, Wenqi
    Li, Jiahui
    Du, Yikuan
    Liu, Yi
    Yang, Chun
    HELIYON, 2024, 10 (14)
  • [24] Adverse events associated with brolucizumab: a disproportionality analysis of the FDA adverse event reporting system (FAERS)
    Xiong, Xiaomei
    Zhang, Xiuwen
    Li, Xiaoxia
    Huang, Taomin
    EXPERT OPINION ON DRUG SAFETY, 2024, 23 (11) : 1447 - 1452
  • [25] Cardiac adverse events associated with quetiapine: Disproportionality analysis of FDA adverse event reporting system
    Shu, Yamin
    Ding, Yiling
    Liu, Lulu
    Zhang, Qilin
    CNS NEUROSCIENCE & THERAPEUTICS, 2023, 29 (09) : 2705 - 2716
  • [26] A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS)
    Shu-peng Zou
    Hai-yun Yang
    Meng-ling Ouyang
    Qian Cheng
    Xuan Shi
    Ming-hui Sun
    BMC Pharmacology and Toxicology, 24
  • [27] Fosfomycin-associated adverse events: A disproportionality analysis of the FDA Adverse Event Reporting System
    Yang, Luxuan
    Zhang, Wenyong
    Shen, Xiujuan
    Liu, Meiqin
    Wu, Meiying
    Xiao, Dan
    DRUG DISCOVERIES AND THERAPEUTICS, 2025,
  • [28] A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS)
    Zou, Shu-peng
    Yang, Hai-yun
    Ouyang, Meng-ling
    Cheng, Qian
    Shi, Xuan
    Sun, Ming-hui
    BMC PHARMACOLOGY & TOXICOLOGY, 2023, 24 (01):
  • [29] Adverse Events of Desvenlafaxine Using FDA Adverse Events Reporting System
    Karydes, H. C.
    Leikin, J. B.
    CLINICAL TOXICOLOGY, 2010, 48 (06) : 664 - 664
  • [30] Adverse events associated with herbal medicine products reported in the Korea Adverse Event Reporting System from 2012 to 2021
    Choi, Yujin
    Shin, Hyeun-Kyoo
    FRONTIERS IN PHARMACOLOGY, 2024, 15
12345